Claims for Patent: 5,665,561

Summary for Patent: 5,665,561

Title:	Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
Abstract:	The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, this invention relates to the identification of the minimum receptor targets of pneumococcal adherence to pulmonary and vascular endothelium, and to compositions and methods for preventing such adherence. In particular, the invention relates to the ability of one or more carbohydrate entities having the following motif or motifs: a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, and an N-acetyl-D-glucosamine motif, effective to induce elution of adherent S. pneumoniae from host cells. In particular, a composition containing all three motifs can elute about 100% of pneumococcal bacteria from lung epithelial cells, and from venous endothelial cells. In a particular embodiment, a pharmaceutical composition of the invention can be used to treat pneumococcal infections in which the host cells are lung epithelial cells. For use in blocking adherence to, or eluting adherent bacteria from, lung epithelial cells, the pharmaceutical composition is an aerosol formulation. The invention further provides formulations for parenteral administration for treating systemic blood-borne infections by preventing or reversing binding to venous endothelial cells. The invention further relates to methods and kits for determining the presence of pneumococci in a biological sample from a subject.
Inventor(s):	Tuomanen; Elaine I. (New York, NY), Cundell; Diana R. (New York, NY)
Assignee:	The Rockefeller University (New York, NY)
Application Number:	08/254,577
Patent Claims:	1. A pharmaceutical composition comprising an amount of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif effective to induce elution of adherent Streptococcus pneumoniae from host cells, an amount of a second carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif effective to induce elution of adherent S. pneumoniae from host cells, and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, further comprising an amount of a second carbohydrate containing an N-acetyl-D-glucosamine motif effective to induce elution of adherent S. pneumoniae from host cells. 3. The pharmaceutical composition of claim 1 or 2 in which the carbohydrate is selected from the group consisting of forssman glycolipid and globoside. 4. The pharmaceutical composition of claim 1 in which the third carbohydrate is N-acetyl-D-glucosamine. 5. The pharmaceutical composition of claim 1 or 2 further comprising an amount of a carbohydrate selected from the group consisting of mannose, N-acetyl-galactose, mannose-D-mannose, and methyl-.alpha.-D-mannopyranoside effective to inhibit binding of S. pneumoniae to host cells. 6. The pharmaceutical composition according to claim 1 or 2 in which the carbohydrate or carbohydrates are multivalent. 7. The pharmaceutical composition of claim 1 or 2, in which the pharmaceutical composition is an aerosol formulation, which formulation contains a dispersant. 8. The pharmaceutical composition of claim 7 in which the dispersant is a surfactant. 9. The pharmaceutical composition of claim 7, which is a dry powder aerosol formulation, in which the carbohydrate or carbohydrates are present in finely divided powder. 10. The pharmaceutical composition of claim 9 which further comprises a bulking agent. 11. The pharmaceutical composition of claim 7, which is a liquid aerosol formulation further comprising a pharmaceutically acceptable diluent. 12. The pharmaceutical composition of claim 11 in which the diluent is selected from the group consisting of sterile water, saline, buffered saline, and dextrose solution. 13. The pharmaceutical composition of claim 1 or 2 in which the host cell is selected from the group consisting of lung epithelial cells and vascular endothelial cells. 14. A method for preventing or treating an infection with S. pneumoniae comprising administering to a subject in need of treatment for an infection with S. pneumoniae an amount of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif effective to induce elution of adherent S. pneumoniae from host cells. 15. The method according to claim 14, further comprising administering an amount of a second carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif effective to induce elution of adherent S. pneumoniae from host cells. 16. The method according to claim 14, further comprising administering an amount of a second carbohydrate containing an N-acetyl-D-glucosamine motif effective to induce elution of adherent S. pneumoniae from host cells. 17. The method according to claim 14, further comprising administering an amount of a third carbohydrate containing an N-acetyl-D-glucosamine motif effective to induce elution of adherent S. pneumoniae from host cells. 18. The method according to claim 14, 15, 16 or 17 in which the carbohydrate is selected from the group consisting of forssman glycolipid and globoside. 19. The method according to claim 15 or 17 in which the second carbohydrate is selected from the group consisting of asialo-GM1 and asialo-GM2. 20. The method according to claim 17 in which the third carbohydrate is N-acetyl-D-glucosamine. 21. The method according to claim 14, 15, 16, or 17 further comprising administering an amount of a carbohydrate selected from the group consisting of mannose, N-acetyl-galactose, mannose-D-mannose, and methyl-.alpha.-D-mannopyranoside effective to inhibit binding of S. pneumoniae to host cells. 22. The method according to claim 14, 15, 16 or 17 in which the carbohydrate or carbohydrates are multivalent. 23. The method according to claim 14, 15, 16, or 17 in which the administering comprises atomizing and inhaling the carbohydrate or carbohydrates. 24. The method according to claim 23 in which the atomizing is nebulizing. 25. The method according to claim 14, 15, 16, or 17 in which the administering comprises injecting the carbohydrate or carbohydrates intravenously. 26. A method for detecting the presence of S. pneumoniae in a sample from a subject comprising detecting the binding of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif to S. pneumoniae. 27. The method according to claim 26, further comprising detecting the binding of a second carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif to S. pneumoniae. 28. The method according to claim 26, further comprising detecting the binding of a third carbohydrate containing an N-acetyl-D-glucosamine S. pneumoniae bacteria. 29. The method according to claim 27, further comprising detecting the binding of a third carbohydrate containing an N-acetyl-D-glucosamine S. pneumoniae bacteria. 30. The method according to claim 26, 27, 28, or 29 in which the carbohydrate is selected from the group consisting of forssman glycolipid and globoside. 31. The method according to claim 27 or 29 in which the second carbohydrate is selected from the group consisting of asialo-GM1 and asialo-GM2. 32. The method according to claim 28 or 29 in which the third carbohydrate is N-acetyl-D-glucosamine. 33. The method according to claim 26, 27, 28, or 29 in which the carbohydrate or carbohydrates are multivalent. 34. The method according to claim 26, 27, 28, or 29 in which at least one carbohydrate is labeled. 35. The method according to claim 26, 27, 28, or 29 in which at least one carbohydrate is attached to a solid phase support. 36. A kit for detecting the presence of S. pneumoniae in a sample from a subject comprising: (a) a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif; and (b) means for detecting binding of the S. pneumoniae bacterium in a sample from the subject. 37. The kit of claim 36, further comprising: (c) a second carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif; and (d) means for detecting binding of the second carbohydrate to the S. pneumoniae. 38. The kit of claim 36, further comprising: (e) a second carbohydrate containing a disaccharide N-acetyl-D-glucosamine motif; and (f) means for detecting binding of the third carbohydrate to the S. pneumoniae. 39. The kit of claim 37, further comprising: (e) a third carbohydrate containing a disaccharide N-acetyl-D-glucosamine motif; and (f) means for detecting binding of the third carbohydrate to the S. pneumoniae. 40. The kit of claim 36, 37, 38, or 39 in which at least one carbohydrate is labelled. 41. The kit of claim 36, 37, 38, or 39 in which at least one carbohydrate is attached to a solid phase support. 42. The method according to claim 16 in which the second carbohydrate is N-acetyl-D-glucosamine.

Details for Patent 5,665,561

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23